Peripheral blood T cell alterations and their prognostic role in newly diagnosed primary central nervous system lymphoma

Recruiting

Conditions: C83.3
Diffuse large B-cell lymphoma

Registration Number: DRKS00025210

Lead Sponsor: niversitätsklinik für Hämatologie und Onkologie

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 90

Inclusion Criteria

1. Immunocompetent patients with newly diagnosed PZNSL =18 years
- Histologically confirmed diagnosis of DLBCL according to WHO by a local pathologist
- Chemotherapy-eligible patients
2. Immunocompetent patients with newly diagnosed nodal DLBCL =18 years of age
- Histologically confirmed diagnosis of DLBCL according to WHO by a local pathologist
- Chemotherapy-eligible patients
3. Healthy volunteers =18 years of age
Written informed consent from patients and healthy volunteers or authorized legal carers in the event that the patient or volunteer is unable to provide information

Exclusion Criteria

ad IC 1.
- Congenital or acquired immune deficiencies, including HIV infection and previous organ or stem cell transplantation
- Lymphoma manifestation outside the central nervous system
ad IC 2.
- Congenital or acquired immune deficiencies, including HIV infection and previous organ transplants
ad IC 3.
- Congenital or acquired immune deficiencies, including HIV infection and previous organ or stem cell transplantation
- Acute infection or illness in the last 4 weeks (e.g. heart attack, broken bone, surgery, etc.)
- Known chronic infection (e.g. hepatitis B / C etc.)
- Known malignancy, with the exception of one that was treated with curative intent and had no evidence of active disease for> 2 years prior to the start of the study
- Known autoimmune disease
- Pregnant or breastfeeding participants

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Assessment of changes in peripheral T cell counts and their subtypes during and at the end of treatment in patients with PCNSL

Secondary Outcome Measures

Name	Time	Method
- Investigation of peripheral T cell counts and their subtypes in newly diagnosed patients with PCNSL and their correlation with prognostic factors and survival<br><br>- Investigation of the correlation between the Treg number and inflammatory cytokines in peripheral blood mononuclear cells (PMNC)<br>- Carrying out the above studies in patients with nodal DLBCL and healthy volunteers and comparing them with the results in PCNSL patients<br>- Investigation of possible differences compared to HIV + PCNSL patients as indicated in the literature